

Special Issue

Advances in the Management of Diabetic Nephropathy

Message from the Guest Editors

Diabetic nephropathy is a serious kidney-related complication of diabetes mellitus. About 25% of people with diabetes eventually develop kidney disease, and diabetes is also a leading cause of end-stage renal disease. The molecular and cellular basis of this renal disease is poorly understood, and this knowledge gap contributes to the suboptimal treatment options available for these patients. Improved understanding of the pathogenesis of diabetic nephropathy is urgently needed to catalyze the development of novel therapeutics. Current therapeutic regimens for these patients include ACE inhibitors, ARBs, and statins that can minimize the effects of the illness but not prevent it. However, side effects to these agents often exceed their overall efficacy. Thus, there is a clear medical need for new therapeutic strategies to improve kidney function in diabetic patients. In this Special Issue of *Pharmaceuticals*, we are inviting original as well as review articles to deepen our insight into the new pathophysiologic pathways, mechanisms, and advances in therapeutic approaches in the management of diabetic nephropathy.

Guest Editors

Dr. Swayam Prakash Srivastava

Department of Pediatrics (Nephrology), Vascular Biology & Therapeutics, Yale University | YU, New Haven, CT, USA

Dr. Surya Pandey

Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA

Deadline for manuscript submissions

closed (31 December 2021)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/56660

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)